Explainable AI Frameworks for Patient-Level Claims Data Analytics

Abstract

Artificial intelligence-driven analytics applied to patient‑level healthcare claims data have become central to pharmaceutical decision‑making, enabling prediction of treatment adherence, therapy switching and longitudinal patient behavior. However, the increasing reliance on complex machine learning models has introduced significant concerns related to transparency, interpretability and trust-particularly in regulated environments where decisions influence patient access, real‑world evidence generation and strategic planning.

This study proposes a comprehensive explainable artificial intelligence (XAI) framework tailored for patient‑level claims data analytics in pharmaceutical contexts. The framework integrates high‑performance predictive modeling with post‑hoc interpretability techniques, including feature attribution and local explanation methods, to ensure model outputs remain transparent, clinically meaningful and decision‑relevant. In addition, a dedicated governance and auditability layer is embedded to support regulatory compliance, traceability and responsible AI deployment across the analytics lifecycle.

By structuring explainability as a first‑class system capability-rather than an afterthought-the proposed framework enables stakeholders to understand not only what predictions are generated, but why they are produced and how they can be acted upon. This work contributes to the growing body of trustworthy AI research by offering a scalable, enterprise‑ready approach that balances predictive performance with interpretability, supporting real‑world evidence development and patient‑centric pharmaceutical analytics.

Keywords: Explainable AI, Healthcare Claims Data, Patient Behavior Analytics, Model Interpretability, Pharmaceutical Analytics, Treatment Adherence, Real World Evidence

1. Introduction

Healthcare claims data have emerged as one of the most valuable sources of real‑world data for understanding patient‑level healthcare utilization, treatment pathways and cost dynamics across large populations. Generated through insurance billing and administrative processes, claims datasets capture detailed longitudinal records of diagnoses, procedures, prescription activity and provider interactions, enabling sustained observation of patient behavior over time¹. As a result, claims data play a foundational role in pharmaceutical analytics, health economics, outcomes research and real‑world evidence (RWE) generation.

The growing scale and availability of patient‑level claims data have accelerated the adoption of advanced analytical methods aimed at predicting clinically and commercially relevant outcomes such as medication adherence, treatment switching, hospitalization risk and disease progression². Machine learning models have become central to these efforts, allowing pharmaceutical organizations to identify complex patterns within high‑dimensional claims datasets that are difficult to capture using traditional statistical techniques³. In practice, such models support critical decision‑making processes, including patient segmentation, intervention targeting, market access planning and post‑market effectiveness assessment.

Despite these advances, the increasing use of sophisticated machine learning techniques has introduced a major challenge: the opacity of black‑box models. Many high‑performing approaches, including ensemble methods and neural networks, provide limited insight into the reasoning behind their predictions^4,5. In pharmaceutical and healthcare settings-where analytical outputs directly influence patient care strategies, regulatory submissions and payer engagement-this lack of transparency can undermine trust, hinder adoption and complicate compliance requirements.

Explainable artificial intelligence (XAI) has emerged as a critical response to these concerns, aiming to make complex model behavior understandable to human stakeholders. Techniques such as feature attribution, surrogate models and local explanations offer mechanisms to interpret predictions without sacrificing model performance⁶. However, in many applied settings, explainability is implemented in an ad hoc or fragmented manner, detached from broader analytics workflows, governance standards and operational decision‑making needs.

In pharmaceutical claims analytics, this fragmentation is particularly problematic. Existing approaches often focus narrowly on model performance or explanation techniques in isolation, failing to address the full lifecycle of AI deployment-from data preprocessing and modeling to explanation generation, auditability and regulatory defensibility. Moreover, current research rarely frames explainability as a decision‑enabling capability, aligned with real‑world pharmaceutical use cases such as adherence intervention design, treatment optimization and evidence‑based strategy development.

To address these gaps, this study proposes a structured explainable AI framework specifically designed for patient‑level claims data analytics in pharmaceutical environments. The framework integrates predictive modeling with interpretable explanation techniques and embeds governance mechanisms that ensure transparency, traceability and compliance across the analytics pipeline⁷. The contributions of this work are threefold:

·       It introduces a unified architectural framework combining data processing, modeling, explainability and governance;

·       It demonstrates how explainability enhances the usability and trustworthiness of AI‑driven insights in pharmaceutical decision‑making; and

·       It provides a scalable foundation for responsible AI adoption in real‑world evidence and patient‑centric analytics.

2. Literature Review

2.1. Overview of explainable AI techniques

Explainable artificial intelligence (XAI) has emerged as a critical area of research in response to the growing adoption of complex machine learning models whose internal decision processes are difficult to interpret. High‑performing algorithms-such as ensemble methods and deep neural networks-often operate as black boxes, creating challenges in domains where decision transparency is essential⁴. To address this gap, a range of explainability techniques has been developed to provide insight into model behavior without sacrificing predictive performance.

Among the most widely adopted methods are Local Interpretable Model‑Agnostic Explanations (LIME) and Shapley Additive Explanations (SHAP). LIME generates local, instance‑level explanations by approximating the behavior of complex models with simpler surrogate models in the vicinity of a specific prediction². SHAP, grounded in cooperative game theory, assigns contribution values to individual features in a manner that is both consistent and theoretically sound⁶. Other commonly used techniques include partial dependence plots (PDPs), counterfactual explanations and rule‑based surrogate models, each offering varying levels of interpretability, scope (local vs. global) and computational complexity.

Collectively, these approaches aim to bridge the gap between predictive accuracy and human‑understandable reasoning. However, their practical value depends not only on theoretical soundness but also on their ability to support real decision workflows-particularly in regulated and high‑impact environments such as healthcare and pharmaceuticals.

2.2. Explainable AI in healthcare applications

The application of explainable AI within healthcare has expanded rapidly across domains such as clinical risk prediction, diagnostic support, disease prognosis and treatment planning. In these contexts, interpretability is essential for validating model outputs, ensuring clinical relevance and supporting trust among practitioners and patients alike⁸. XAI techniques enable stakeholders to identify the key drivers behind predictions-such as risk factors, treatment indicators or utilization patterns-thereby supporting more transparent and accountable decision‑making.

Recent studies demonstrate that embedding explainability within healthcare AI systems improves model validation, facilitates bias detection and enhances adoption among clinicians and healthcare administrators⁹. Importantly, explainability also plays a critical role in aligning AI outputs with established clinical knowledge, helping domain experts assess whether predictions are plausible and actionable rather than statistically opaque.

Despite this progress, much of the existing healthcare XAI literature focuses on clinical or imaging‑centric applications. Comparatively less attention has been given to real‑world administrative data, such as claims, where interpretability must support not only clinicians but also pharmaceutical decision‑makers, regulators and policy stakeholders.

2.3. Claims data analytics and patient-level prediction

Healthcare claims data analytics centers on extracting insight from large‑scale administrative records that capture patient interactions with the healthcare system over time. Claims‑based machine learning models are widely used to predict outcomes such as medication adherence, treatment switching, hospitalization likelihood and cost trajectories¹⁰. These predictions are particularly valuable in pharmaceutical contexts, where understanding patient‑level dynamics informs intervention strategies, post‑market evaluation and real‑world evidence generation.

The high dimensionality and longitudinal structure of claims data often necessitate the use of advanced machine learning models capable of capturing non‑linear relationships and temporal dependencies. While such models deliver strong predictive performance, they frequently reduce interpretability-limiting visibility into how patient attributes, utilization patterns and treatment histories interact to produce specific outcomes. This trade‑off becomes especially problematic in pharmaceutical decision‑making, where predictions must be explainable to support regulatory submissions, payer engagement and patient‑centric program design.

2.4. Limitations of existing approaches

Despite the maturation of XAI techniques, several limitations persist in their application to healthcare claims analytics. First, many interpretability methods are applied post hoc and operate independently of the broader analytics lifecycle. As a result, explanations may not fully capture the internal logic of predictive models or may vary significantly across different interpretation techniques, leading to ambiguity in decision support⁵.

Second, existing approaches often lack integration with governance and compliance mechanisms. In regulated environments, explainability must extend beyond feature attribution to include traceability of data inputs, model versions, assumptions and outputs over time. Current studies frequently emphasize model accuracy and interpretability in isolation, without addressing auditability, reproducibility or alignment with real‑world evidence standards⁷.

Finally, many XAI implementations are not designed with enterprise scalability in mind. Computational cost, explanation instability and limited support for longitudinal analysis can hinder adoption in real‑world pharmaceutical analytics platforms that operate at population scale.

2.5. Research gap synthesis

The literature reveals a clear gap in the development of integrated explainable AI frameworks tailored to patient‑level healthcare claims data analytics. While individual explainability techniques such as SHAP and LIME are well established, their application remains fragmented and insufficiently connected to governance, auditability and decision workflows in pharmaceutical environments.

Specifically, there is a lack of end‑to‑end frameworks that unify data preprocessing, predictive modeling, explainability, continuous monitoring and regulatory compliance within a single operational architecture. Addressing this gap requires moving beyond ad hoc interpretation of black‑box models toward system‑level explainability, where transparency is embedded throughout the analytics lifecycle and aligned with real‑world pharmaceutical decision‑making.

This research responds to that need by proposing a comprehensive explainable AI framework that balances predictive performance with interpretability and governance, supporting trustworthy, patient‑centric and enterprise‑ready claims data analytics (Table 1).

Table 1: Summary of Existing XAI Methods in Healthcare.

3. Theoretical Foundation

3.1. Interpretability vs Explainability

Interpretability and explainability are closely related but conceptually distinct constructs in artificial intelligence. Interpretability refers to the inherent transparency of a model’s internal mechanics, allowing users to directly understand how inputs are transformed into outputs. Models such as linear regression or decision trees are often considered interpretable because their structure and decision logic can be examined directly¹⁰. However, these models may lack the expressive power required to capture complex, non‑linear relationships common in high‑dimensional healthcare claims data.

Explainability, by contrast, addresses the challenge of understanding complex or opaque models by applying external techniques that make their behavior intelligible without exposing internal structure¹¹. In practice, explainability enables stakeholders to reason about predictions from high‑performing models-such as gradient boosting machines and neural networks-using post hoc interpretation methods. This distinction is particularly relevant in pharmaceutical analytics, where predictive accuracy alone is insufficient unless outputs can be explained, validated and defended across medical, regulatory and business contexts.

For patient‑level claims analytics, explainability therefore represents a strategic capability rather than a technical enhancement. It enables organizations to retain advanced modeling performance while meeting the transparency and accountability expectations required for real‑world evidence (RWE) generation and decision support.

3.2. Trust, Fairness and Accountability in healthcare AI

Trust is a foundational requirement for the adoption of AI systems in healthcare and pharmaceutical decision‑making. Unlike consumer analytics, healthcare AI influences decisions that affect patient access, treatment pathways and population‑level outcomes. Explainability contributes directly to trust by enabling stakeholders to assess whether model predictions are plausible, consistent with domain knowledge and supported by meaningful data signals⁸.

Fairness is a critical related dimension, particularly in patient‑level analytics where biases embedded in historical claims data may lead to unequal outcomes across demographic or clinical subgroups. Explainable AI techniques support fairness assessment by revealing feature contributions and highlighting whether sensitive attributes or proxies disproportionately influence predictions⁹. Without explainability, such biases may remain hidden, undermining both ethical responsibility and regulatory credibility.

Accountability refers to the ability to trace, justify and audit decisions generated by AI systems. In pharmaceutical environments, accountability extends beyond model development to include how predictions are used in downstream processes such as patient targeting, adherence interventions and evidence planning. Explainability mechanisms provide the transparency required to document why decisions were made and to support internal governance, external review and regulatory scrutiny.

Together, trust, fairness and accountability form a triad of responsible AI principles that are especially relevant in claims‑based analytics, where decisions must be both scalable and defensible.

3.3. Regulatory and governance perspectives

The application of AI to healthcare and pharmaceutical analytics operates within an increasingly stringent regulatory and governance landscape. Regulatory bodies and payers place growing emphasis on the credibility, reproducibility and transparency of real‑world evidence used to support decision‑making. As AI models become more deeply embedded in evidence generation and strategy formulation, the ability to explain and audit their outputs becomes essential. Governance frameworks play a central role in operationalizing explainability within this context. Effective governance encompasses model documentation, version control, performance monitoring, bias detection and traceability of data inputs and analytical assumptions⁷. In patient‑level claims analytics, governance ensures that predictions and explanations can be reviewed, reproduced and validated over time—rather than existing as one‑off analytical artifacts.

Importantly, explainability strengthens governance by linking technical model behavior to documented decision logic. It enables organizations to demonstrate not only what a model predicts, but how those predictions were derived and whether they align with established clinical and business reasoning. This alignment is critical for supporting regulatory submissions, payer engagement and responsible use of AI in population‑scale analytics.

Within this theoretical framework, explainability is therefore not treated as an optional model add‑on, but as a core pillar of trustworthy, enterprise‑ready AI systems in pharmaceutical claims analytics.

4. Proposed explainable AI framework

4.1. Framework overview (Architecture and Design Principles)

The proposed explainable AI framework is designed as a modular, layered enterprise architecture that integrates patient‑level healthcare claims data, predictive modeling, explainability mechanisms and governance controls into a single, cohesive analytics system. The primary objective of the framework is to ensure that predictions related to patient behavior-such as treatment switching, medication adherence and healthcare utilization-are not only accurate but also transparent, auditable and decision‑ready⁵.

Unlike ad hoc XAI implementations that focus narrowly on model interpretation, this framework adopts a governance‑by‑design approach, where explainability, traceability and accountability are embedded across the full analytics lifecycle. The architecture supports end‑to‑end workflows, beginning with claims data ingestion and extending through prediction, explanation, monitoring and regulatory defensibility. Each layer performs a well‑defined function while maintaining interoperability through standardized data flows, metadata capture and feedback mechanisms.

From an enterprise deployment perspective, the framework is designed to operate at population scale, support longitudinal analytics and integrate seamlessly into pharmaceutical decision‑making environments that require reproducibility, role‑based access and auditability. The layered design enables organizations to evolve individual components-such as models or explanation techniques-without destabilizing the overall system.

4.2. Framework components

4.2.1. Data layer: Claims data ingestion and preprocessing

The data layer forms the foundation of the framework and is responsible for ingesting, standardizing and preparing patient‑level healthcare claims data from multiple sources, including medical claims, pharmacy claims and provider billing records³. Given the longitudinal and heterogeneous nature of claims data, this layer performs critical preprocessing tasks such as data cleaning, normalization, feature extraction and temporal alignment.

Key data elements include diagnosis codes, procedure codes, prescription histories, refill timing, healthcare utilization metrics and demographic attributes. To support downstream explainability and governance, the data layer also captures metadata and lineage information, enabling traceability of how raw records are transformed into analytical features. This foundation is essential for ensuring consistency across model training, prediction generation and explanation outputs.

4.2.2. AI modeling layer: Predictive analytics at patient scale

The AI modeling layer applies machine learning algorithms to generate patient‑level predictions aligned with pharmaceutical analytics use cases, such as medication adherence risk, likelihood of treatment switching and hospitalization propensity. Models including gradient boosting methods (e.g., XGBoost), random forests and neural networks are used to capture complex, non‑linear relationships inherent in high‑dimensional claims data¹².

Model selection within this layer balances predictive performance with explainability compatibility and operational robustness. Importantly, models are not treated as isolated artifacts; they are deployed within a controlled lifecycle that includes versioning, performance monitoring and validation checkpoints. This design supports repeatability and ensures that model outputs remain consistent and defensible over time, especially when used in real‑world evidence generation or strategic decision‑making.

4.2.3. Explainability layer: Structured transparency and model insight

The explainability layer operationalizes transparency by integrating post hoc interpretability techniques as a native system capability rather than an external analytic step. Techniques such as SHAP and LIME are used to generate both global explanations (e.g., feature importance trends across populations) and local explanations (e.g., drivers of individual patient predictions).

SHAP values quantify the contribution of each feature to a prediction in a consistent and theoretically grounded manner, enabling population‑level insight and cross‑model comparison⁶. LIME complements this by providing localized explanations for individual predictions, supporting case‑level reasoning and validation. Together, these methods enable stakeholders to understand why predictions are produced and assess whether they align with clinical knowledge, business logic and ethical expectations.

Crucially, explanation artifacts are treated as first‑class outputs, stored, versioned and linked to their corresponding data inputs and model versions. This design ensures explanations can be audited, reproduced and reviewed—an essential requirement for enterprise adoption and regulatory confidence.

4.2.4. Governance layer: Accountability, Compliance and monitoring

The governance layer enforces accountability and regulatory alignment across the analytics lifecycle. It establishes mechanisms for audit trails, bias detection, performance tracking and documentation of analytical assumptions. This layer ensures that every prediction and explanation can be traced back to its underlying data, model configuration and execution context⁷.

Governance functions include continuous monitoring of model drift, validation of explanation stability and enforcement of compliance standards related to data privacy and real‑world evidence usage. Role‑based controls enable appropriate access to predictions and explanations, supporting both internal governance and external review. By embedding governance directly into the framework, explainability becomes operational rather than aspirational-supporting trust at scale.

4.3. Feedback loop for continuous learning and control

A key strength of the proposed framework is its closed feedback loop, which connects governance and performance monitoring back to the data, modeling and explainability layers. Observed outcomes-such as changes in patient behavior, intervention effectiveness or shifts in data distributions-are fed back into the system to recalibrate models, refine features and validate explanation relevance¹³.

This continuous learning mechanism enables the framework to adapt to evolving healthcare dynamics while maintaining analytical consistency and control. Importantly, updates are governed rather than automatic: changes are logged, reviewed and validated to ensure that adaptability does not compromise transparency or trust. This balance between agility and governance is especially critical in pharmaceutical environments, where both innovation and accountability are required.

Figure 1: Conceptual framework illustrating the integration of healthcare claims data, AI modeling, explainability mechanisms and governance layers for transparent patient-level analytics. The framework highlights the flow from data ingestion to predictive outputs, including patient behavior, treatment switching and adherence, with embedded explainability and feedback loops for continuous model improvement.

Figure 2: Layered architecture of the proposed explainable AI system for healthcare claims analytics. The diagram presents the hierarchical structure consisting of the data layer, AI modeling layer, explainability layer and governance layer, with bidirectional data flow and feedback mechanisms to support continuous learning, auditability and regulatory compliance.

5. Research Methodology

This study adopts a structured, decision‑oriented research methodology to design and evaluate an explainable artificial intelligence framework for patient‑level healthcare claims data analytics. Rather than focusing exclusively on predictive accuracy, the methodology emphasizes decision validity, explainability quality and deployment readiness-criteria that are essential for real‑world adoption in pharmaceutical analytics environments⁸.

5.1. Data foundation and analytical context

The analysis is based on longitudinal healthcare claims data, integrating medical and pharmacy records that capture patient interactions across diagnoses, prescriptions and healthcare utilization over time⁹. The dataset includes structured attributes such as diagnosis codes, procedure codes, prescription histories, refill timing and demographic characteristics, enabling end‑to‑end tracking of patient treatment trajectories and behavioral patterns¹⁴.

From a pharmaceutical analytics perspective, the longitudinal nature of claims data is particularly critical because it allows for observation of temporal dynamics, including changes in adherence behavior, treatment switching events and utilization patterns. These longitudinal properties directly support real‑world evidence generation and patient‑centric decision‑making rather than static, cross‑sectional analysis¹¹.

5.2. Feature engineering for explainability and decision relevance

Feature engineering is performed with explicit consideration of interpretability and decision relevance, not solely predictive power. Derived variables are constructed to represent clinically and operationally meaningful dimensions of patient behavior and health status.

Medication adherence is quantified using established measures such as proportion of days covered (PDC), providing interpretable indicators of therapy compliance. Treatment switching is captured through features reflecting the frequency, timing and sequence of regimen changes¹². Clinical complexity is incorporated using comorbidity indices derived from diagnosis codes, while healthcare utilization is represented through inpatient admissions, outpatient visits and pharmacy activity.

Temporal features are engineered to capture trends and transitions in patient behavior over time, allowing models to reflect evolving risk rather than static snapshots⁵. This feature design ensures that downstream explanations can be meaningfully interpreted by domain experts and aligned with pharmaceutical decision workflows.

5.3. Predictive modeling with explainability compatibility

The predictive modeling process involves the application and comparison of multiple machine learning algorithms capable of handling high‑dimensional, structured claims data. Models evaluated include gradient boosting (e.g., XGBoost), random forest classifiers and neural network architectures, each selected for their ability to capture complex non‑linear relationships¹².

Model selection criteria extend beyond performance metrics to include stability, explainability compatibility and operational robustness. Gradient boosting models, in particular, are emphasized due to their strong performance in structured data settings and compatibility with post‑hoc explanation techniques. Models are trained, validated and versioned in a controlled manner to support reproducibility and lifecycle management-both critical for enterprise deployment.

5.4. Explainability integration and evaluation

Explainability is embedded directly into the analytical pipeline using post‑hoc interpretability techniques rather than being applied as an external or ad hoc step. SHAP is employed to generate both global and local explanations by quantifying the contribution of individual features to model predictions in a consistent and theoretically grounded manner^6,7.

Complementarily, LIME is applied to produce localized, instance‑level explanations by approximating model behavior in the vicinity of individual predictions². Together, these techniques support explanation at both population and patient levels-an essential requirement for pharmaceutical analytics where decisions must be justified across cohorts as well as individual cases.

Explainability outputs are evaluated not only for interpretability, but also for:

·       Stability across model runs and datasets.

·       Consistency between explanation methods.

·       Plausibility relative to clinical and domain knowledge.

This evaluation ensures that explanations are reliable and actionable rather than purely descriptive.

5.5. Evaluation framework: Beyond model accuracy

The framework is evaluated using a multi‑dimensional assessment strategy that reflects real‑world pharmaceutical decision requirements. Predictive performance is measured using standard classification metrics, including accuracy, precision, recall and area under the receiver operating characteristic curve. However, these metrics are treated as necessary but insufficient conditions for deployment.

To assess decision validity, interpretability evaluation focuses on whether explanations:

·       Identify clinically meaningful drivers of behavior.

·       Remain consistent across patient subgroups.

·       Support defensible intervention planning.

Trustworthiness is evaluated through transparency, reproducibility and alignment with established medical and pharmaceutical knowledge¹. This approach ensures that model outputs and explanations are suitable for consumption by non‑technical stakeholders involved in patient programs, evidence planning and strategic decision‑making.

5.6. Enterprise deployment readiness

Beyond analytical performance, the methodology explicitly considers enterprise deployment readiness. This includes assessing computational scalability of explanation techniques, reproducibility of results and compatibility with governance and compliance requirements.

Explainability artifacts are treated as first‑class outputs-stored, versioned and linked to specific data inputs and model configurations. Continuous monitoring mechanisms are assumed to track model performance, explanation stability and drift over time, supporting responsible deployment in dynamic healthcare environments (Ahmad et al., 2018).

By aligning technical evaluation with governance, trust and operational scalability, the methodology ensures that the proposed framework is suitable not only for experimental validation but also for real‑world pharmaceutical analytics platforms (Table 2).

Table 2: Dataset Variables and Features.

6. Experimental Results and Analysis

6.1. Predictive performance as decision enablement

The predictive models were evaluated using standard classification metrics, including accuracy, precision, recall and area under the receiver operating characteristic curve (AUC). While these metrics provide an essential baseline for assessing statistical performance, they are interpreted here primarily in terms of decision enablement rather than algorithmic comparison alone.

Among the evaluated models, gradient boosting (XGBoost) demonstrated the strongest overall performance, exhibiting high accuracy and robustness in predicting patient‑level outcomes such as medication adherence and treatment switching. Neural network models achieved comparable performance but required significantly higher computational resources, while random forest models offered a balanced trade‑off between performance stability and interpretability. Logistic regression, although more transparent by design, exhibited lower predictive strength, limiting its suitability for complex claims‑based decision scenarios.

From a pharmaceutical analytics perspective, these findings indicate that high‑performing models are necessary but not sufficient. The selected models must not only predict outcomes reliably, but also support downstream explainability and governance requirements. Gradient boosting models were therefore favored, as they provided strong predictive capability while remaining compatible with explainability techniques essential for responsible deployment.

6.2. Explainability outputs as decision insights

Explainability analysis played a central role in transforming model outputs into actionable decision insights. SHAP‑based global explanations revealed a consistent set of high‑impact drivers across models, including prior medication adherence, refill gaps, comorbidity burden and healthcare utilization frequency. These features align closely with established clinical and pharmaceutical understanding of patient behavior, reinforcing confidence in the model’s reasoning.

At the population level, explainability outputs enabled stakeholders to understand which factors systematically influence outcomes, supporting cohort‑based planning and evidence development. At the patient level, local explanations generated through LIME highlighted how individual characteristics contributed to specific predictions, enabling case‑level assessment and validation.

Rather than serving as descriptive artifacts, explainability outputs were evaluated for decision relevance—specifically, whether they:

·       Identified modifiable drivers suitable for intervention.

·       Remained consistent across patient subgroups.

·       Aligned with domain knowledge and real‑world evidence expectations.

This evaluation confirmed that explainability techniques meaningfully enhanced trust in model outputs and supported their use in pharmaceutical decision workflows.

6.3. Scenario‑driven case analysis

6.3.1. Treatment switching prediction as early warning

In treatment switching prediction scenarios, the framework effectively identified patients at elevated risk based on declining adherence patterns, widening refill gaps, increasing comorbidity complexity and higher healthcare utilization. Explainability outputs consistently showed that refill gap dynamics and recent prescription instability were among the strongest contributors to switching risk.

From a decision‑making standpoint, these insights enable earlier identification of at‑risk patients, allowing pharmaceutical teams to intervene proactively-through patient support programs or evidence‑based engagement strategies-rather than reacting after switching occurs. Importantly, explanation transparency allowed stakeholders to distinguish between clinically driven switching and behaviorally driven patterns, supporting more targeted responses.

6.3.2. Medication adherence risk stratification

In adherence prediction scenarios, the model demonstrated high sensitivity in identifying patients likely to become non‑adherent. SHAP analysis indicated that historical adherence measures, medication complexity and demographic context were the dominant contributors to risk.

These explainable insights enable decision‑makers to move beyond binary risk flags toward interpretable risk stratification, where interventions can be tailored based on why adherence risk is elevated. For example, interventions for patients driven by regimen complexity may differ from those driven by access or utilization instability. This differentiation is critical for designing scalable, patient‑centric adherence strategies.

6.4. Explainability versus black‑box performance trade‑offs

A comparison with non‑explainable (“black‑box”) model deployments demonstrated that the integration of explainability techniques did not result in meaningful degradation of predictive performance. Instead, explainability substantially improved transparency, validation capability and stakeholder confidence without compromising accuracy⁶.

This finding reinforces a key premise of the proposed framework: explainability and performance are not competing objectives in well‑designed pharmaceutical analytics systems. When explainability is embedded into the modeling and governance lifecycle, it strengthens decision quality rather than constraining model capability.

6.5. Implications for real‑world deployment

Beyond numerical evaluation, the experimental analysis highlights how explainable AI frameworks unlock practical value for real‑world pharmaceutical deployment. By linking model predictions to interpretable drivers, the framework supports:

·       Auditable decision‑making aligned with regulatory expectations

·       Cross‑functional adoption across analytics, medical and strategy teams

·       Continuous monitoring and refinement of models based on observed outcomes

These results demonstrate that explainability transforms claims‑based analytics from predictive outputs into defensible, actionable decision intelligence, capable of operating at enterprise scale (Tables 3 and 4).

Table 3: Model Performance Comparison.

Table 4: Explainability Output Summary.

Figure 3: Feature Importance / SHAP Visualization.

(Figure 3) SHAP based feature importance visualization illustrating the contribution of key variables to model predictions in patient-level claims analytics. The chart highlights the relative impact of factors such as adherence history, refill gaps, comorbidity index, age and healthcare utilization on predictive outcomes. Higher SHAP values indicate greater influence on the model’s decision, enabling transparent interpretation of the drivers behind patient behavior predictions, including treatment switching and medication adherence.

7. Discussion

The findings of this study highlight the practical value of integrating explainable AI into patient-level claims data analytics¹¹. From a pharmaceutical decision-making perspective, the ability to interpret model predictions enhances strategic planning, particularly in areas such as patient targeting, adherence improvement programs and treatment optimization. Explainability enables stakeholders to identify the underlying drivers of patient behavior, thereby supporting more informed and evidence-based decisions².

The incorporation of explainability techniques significantly strengthens the role of real-world evidence in healthcare analytics. By providing transparent insights into predictive models, the framework improves the credibility and usability of AI-driven outputs. This is particularly important in regulated environments, where decision-making must be supported by interpretable and auditable evidence.

However, the study also highlights the inherent trade-off between predictive accuracy and interpretability. While complex models such as gradient boosting and neural networks offer higher accuracy, they require additional layers of explanation to ensure transparency. Simpler models, although more interpretable, may not capture the full complexity of claims data. The proposed framework addresses this trade-off by combining high-performance models with robust explainability techniques.

From a deployment perspective, integrating explainable AI into pharmaceutical analytics systems requires careful consideration of infrastructure, scalability and user interface design¹⁴ Organizations must ensure that explanations are not only accurate but also accessible and actionable for decision-makers¹. Additionally, continuous monitoring and updating of models are necessary to maintain performance and relevance over time.

8. Limitations

Despite its contributions, this study has several limitations that merit consideration. First, the quality and completeness of healthcare claims data can significantly influence both predictive accuracy and explanation reliability. Coding inconsistencies, missing data and variability across healthcare systems may affect generalizability and require dataset‑specific adaptation.

Second, while explainability techniques such as SHAP and LIME provide valuable insight, they can introduce computational overhead, particularly in large‑scale, real‑time environments. Enterprise deployments must therefore balance explanation granularity with performance and cost considerations.

Finally organizational readiness remains a non‑technical constraint. Effective adoption of explainable AI requires stakeholder education, alignment across analytics and decision teams and trust in both model outputs and explanations. These factors are critical for translating technical capability into operational impact.

9. Conclusion

This study presents a comprehensive explainable artificial intelligence framework for patient‑level healthcare claims data analytics with direct relevance to pharmaceutical decision‑making. As machine learning models increasingly influence real‑world evidence generation, patient targeting strategies and treatment optimization efforts, the need for transparency, interpretability and accountability has become critical.

The proposed framework addresses this need by integrating high‑performance predictive modeling with robust explainability techniques and embedded governance mechanisms within a unified, scalable architecture. Results demonstrate that advanced models such as gradient boosting and neural networks can be effectively combined with post‑hoc interpretation methods, including SHAP and LIME, without materially compromising predictive performance. More importantly, the explainability layer enables stakeholders to understand the drivers of model predictions, supporting informed, defensible and patient‑centric decision‑making.

By embedding auditability, traceability and monitoring into the analytics lifecycle, the framework aligns AI‑driven insights with regulatory expectations and real‑world evidence standards. The inclusion of feedback loops further enables continuous learning, allowing the system to adapt to evolving patient behavior and healthcare dynamics while maintaining consistency and reliability.

Overall, this work advances the practical application of explainable AI in healthcare claims analytics by demonstrating that interpretability is not a trade‑off against performance, but a prerequisite for responsible, enterprise‑scale deployment. Future research may extend this framework through causal inference, privacy‑preserving learning and federated architectures to further strengthen trust, robustness and scalability in pharmaceutical analytics environments.

10. References

1.     Band SS, Yarahmadi A, Hsu CC, et al. Application of explainable artificial intelligence in medical health: A systematic review of interpretability methods. Informatics in Medicine Unlocked, 2023;40: 101286.

2.     Ribeiro MT, Singh S, Guestrin C. Why should I trust you? Explaining the predictions of any classifier. In Proceedings of the 22nd ACM SIGKDD international conference on knowledge discovery and data mining, 2016: 1135-1144.

3.     Costa B, Georgieva P. Explainable artificial intelligence in healthcare applications: A systematic review. In 2023 International Scientific Conference on Computer Science (COMSCI), 2023: 1-8.

4.     Adadi A, Berrada M. Peeking inside the black-box: a survey on explainable artificial intelligence (XAI). IEEE access, 2018;6: 52138-52160.

5.     Giuste F, Shi W, Zhu Y, et al. Explainable artificial intelligence methods in combating pandemics: A systematic review. IEEE Reviews in Biomedical Engineering, 2022;16: 5-21.

6.     Lundberg SM, Lee SI. A unified approach to interpreting model predictions. Advances in neural information processing systems, 2017;30.

7.     Bharati S, Mondal MRH, Podder P. A review on explainable artificial intelligence for healthcare: Why, how and when? IEEE Transactions on Artificial Intelligence, 2023;5(4): 1429-1442.

8.     Arrieta AB, Díaz-Rodríguez N, Del Ser J, et al. Explainable Artificial Intelligence (XAI): Concepts, taxonomies, opportunities and challenges toward responsible AI. Information fusion, 2020;58: 82-115.

9.     Saraswat D, Bhattacharya P, Verma A, et al. Explainable AI for healthcare 5.0: opportunities and challenges. IEEe Access, 2022;10: 84486-84517.

10.  Sadeghi Z, Alizadehsani R, Cifci MA, et al. A review of explainable artificial intelligence in healthcare. Computers and Electrical Engineering, 2024;118: 109370.

11.  Molnar C. Interpretable machine learning. Lulu. Com, 2020.

12.  Tjoa E, Guan C. A survey on explainable artificial intelligence (xai): Toward medical xai. IEEE transactions on neural networks and learning systems, 2020;32(11): 4793-4813.

13.  Ahmad MA, Eckert C, Teredesai A. Interpretable machine learning in healthcare. In Proceedings of the 2018 ACM international conference on bioinformatics, computational biology and health informatics, 2018: 559-560.

14.  Amin A, Hasan K, Zein-Sabatto S, et al. An explainable ai framework for artificial intelligence of medical things. In 2023 IEEE Globecom Workshops (GC Wkshps), 2023: 2097-2102.

15.  Ghasemi A, Hashtarkhani S, Schwartz DL, et al. Explainable artificial intelligence in breast cancer detection and risk prediction: A systematic scoping review. Cancer Innovation, 2024;3(5): 136.